Resources
961 Results (showing 661 - 670)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 6/2/2023 (updated 3/27/2024)
Blueprints Programs website houses a repository of evidence-based primary prevention programs and resources. You can search for programs that fit the issue you are addressing, the audience you seek to help, as well as the delivery venue.
Posted 5/26/2023 (updated 3/27/2024)
Start your journey to better mental health today and find your support system on FindSupport.gov. Let’s honor the memories of those we have lost and prevent others from managing their mental health challenges alone. If you or someone you know is in a mental health crisis, Text or call 988 or chat 988lifeline.org for free, confidential support 24/7
Posted 5/26/2023 (updated 3/27/2024)
More than 450 clinicians and counselors in rural New England were surveyed about stigma as a barrier to treating patients for opioid used disorder (OUD) as well as practitioners’ beliefs about medications for OUD. Over half (55 percent) ranked stigma as the highest barrier among other factors such as time and staffing, medication diversion, and organizational/clinic barriers.
Posted 5/26/2023 (updated 3/27/2024)
Providers Clinical Support System (PCSS), a Substance Abuse and Mental Health Services Administration-funded grant initiative, announced the release of Practice-Based Guidelines: Buprenorphine in the Age of Fentanyl. The guide gives practitioners a blueprint on treating fentanyl use disorder based on available research combined with emerging clinical experience on the use of buprenorphine in the treatment of individuals using fentanyl and other highly potent synthetic opioids.
Posted 10/23/2023 (updated 3/27/2024)
The 2023 RCORP-CABH Onboarding Packet includes resources, tools, and strategies to support grant-funded activities, along with information on accessing TA. We hope you find the Onboarding Packet helpful as a starting point. Our TA team is here to support you through your grant, so should you have any questions related to this document or other technical assistance needs, please do not hesitate to contact your Technical Expert Lead (TEL).
Posted 5/26/2023 (updated 3/27/2024)
The U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to sever opioid use disorder (OUD). Buprenorphine is a safe and effective medication for OUD treatment.
Posted 5/16/2023 (updated 3/27/2024)
Xylazine, a veterinary tranquilizer not approved for human use, has been increasingly identified in parts of the U.S. illicit drug supply.
Posted 10/23/2023 (updated 3/27/2024)
Posted 5/22/2023 (updated 3/27/2024)
The National Institute of Mental Health (NIMH) provides several behavioral warning signs and symptoms you can look out for in children and youth. While certain behavior can be a part of growing up, the warning signs and symptoms listed by the NIMH may be a reason to contact a health professional. Mental illnesses can be treated and talking with your child or teen can help you identify when to see a health professional.
Posted 10/23/2023 (updated 3/27/2024)
The Reagan-Udall Foundation partnered with the Food and Drug Administration (FDA) for the "Mitigating Risks from Human Xylazine Exposure" virtual and in-person webinar that occurred early October 2023. This public meeting explored real-world experiences and scientific evidence on emerging data trends for human xylazine exposure and examined concrete strategies for drug development and clinical research that directly supports the mitigation and reduction of risks associated with human exposure to xylazine. The meeting materials, recordings, and slides are now available for viewing.